如何让每个人在变老后仍能找到存在的意义，这是老龄化时代留给人类文明的终极考题。在养老引发的跨越代际的社会转型中，每个人都将成为生活的重 构者。 "银发浪潮"，正在改写你我的生活。 数据显示，截至2024年年底，中国 60岁及以上人口 3.1亿人，65 岁及以上人口2.2亿人，占总人口的比重分别为 22%、15.6%，已进入中度老龄化阶段。到 2035 年，中国老年人口数量将超过 4 亿人。 3月23日， 在中国发展高层论坛2025年年会上，民政部副部长唐承沛在演讲时提到，中国老年人口规模已超过世界上绝大多数国家人口总量。未来10年 内，60岁及以上的老年人口将每年净增超过1000万人。 可见，我国正在经历一次规模大、速度快、持续时间长的老龄化进程。 退休不是人生的休止符，而是第二人生的起点，越发具象的生活命题让我们看到，"老龄化"绝非只是统计表格中的数字增长，而是与每个家庭息息相关的 生活必答题。 我们谈论养老，并非想要贩卖焦虑，而是当这件事无法避免地发生在我们的父辈甚至自己身上时，我们可以提供一种生活重构的可能性。这也让我们思 考，应该如何让"老龄化"从现实的社会压力转化为让人重新认识和开发自己的契机，成为 ...

此外，经典的龙角散薄荷味草本润喉糖也广受好评。该产品曾多次登上天猫、京东等多平台润喉糖销量 榜榜首，同样采用了甘草、桔梗等润喉护嗓的天然草本，通过整株研磨技术保留草本活性成分，口感清 凉的同时温润不刺激，长效呵护咽喉健康。 业内健康专家表示，应对流感需要"防"与"治"相结合的综合策略。在做好积极防护的同时，关注咽喉这 类关键部位的健康，是提升个人及家庭整体抗病能力的重要环节。选择像龙角散这样经过市场长期验 证、成分优质且明晰的产品进行适量家庭储备，不失为一种前瞻的健康管理措施。 近日，全国多地疾控部门发布预警，提示流感病毒活动水平明显增强，尤其北方地区流感样病例百分比 持续攀升，宣告本年度的流感季已较往年提前到来。此消息引发公众对呼吸道疾病防控的高度关注，除 采取接种疫苗和常规预防措施外，针对流感典型症状——咽喉不适的早期干预与日常防护也成为公众自 我健康护理的重要环节。在此背景下，百年护嗓品牌龙角散凭借其科学天然的草本配方与温和有效的咽 喉护理效果，正受到越来越多消费者和家庭的青睐。 流感并非普通感冒，其典型症状包括高热、全身酸痛、乏力以及严重的呼吸道症状。其中，咽喉肿痛、 干痒、嘶哑是流感患者最为普遍和痛 ...

Core Viewpoint - The stock price of Tongrentang has experienced fluctuations, with a recent decline of 2.07%, while the company has shown a year-to-date increase of 9.29% in stock price [1][2]. Financial Performance - For the period from January to September 2025, Tongrentang reported a revenue of 4.915 billion yuan, representing a year-on-year decrease of 14.27%. However, the net profit attributable to shareholders increased by 4.45% to 907 million yuan [2]. - The company has distributed a total of 8.321 billion yuan in dividends since its A-share listing, with 2.429 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Tongrentang was 71,100, a slight decrease of 0.14% from the previous period. The average number of circulating shares per person was 15,762, down by 0.67% [2]. - The top ten circulating shareholders include notable entities such as E Fund's ChiNext ETF and Hong Kong Central Clearing Limited, with changes in their holdings observed [3].

Core Viewpoint - The article highlights the rise of fraudulent activities targeting elderly consumers in China's aging market, particularly through private domain live streaming, leading to regulatory actions against misleading promotions [2][10]. Group 1: Regulatory Actions - The Shanghai Baoshan District Market Supervision Administration successfully investigated a case involving false advertising and consumer deception through private domain live streaming [2]. - The enforcement officers found that the promoted product, a compound lactic acid bacteria freeze-dried powder, was falsely advertised to have immediate effects, misleading consumers like Ms. Wang [4][8]. - The authorities determined that the product sold was merely a regular food item, not a drug or health product, and have mandated the cessation of illegal activities with corresponding penalties [8]. Group 2: Marketing Practices - The investigation revealed that during the private live stream, sales personnel emphasized the product's supposed benefits against Helicobacter pylori but failed to show the actual product or provide a direct purchasing link [6]. - Instead, after the live stream, purchase links were sent in WeChat groups with discounts to entice elderly consumers to buy, complicating the enforcement process due to the separation of promotion and actual product [6]. Group 3: Industry Insights - Industry experts note that as the elderly health product market grows, more businesses are using private domain live streaming for marketing, raising concerns about potential misconduct [10]. - The Chinese Consumers Association has identified private domain marketing as a significant area of consumer complaints, particularly regarding counterfeit products and difficulties in consumer rights protection due to incomplete transaction records [10].

Core Viewpoint - The article emphasizes that consumers often fall into the misconception that higher glucosamine content equals higher efficacy. It highlights the importance of a scientifically formulated product, absorption rate, safety certifications, and clinical evidence in determining the effectiveness of glucosamine products [1][2]. Summary by Categories Core Principles for Selecting Glucosamine Products - **Safety as the Baseline: Blue Hat Certification is Irreplaceable**: The "Blue Hat" certification from the National Medical Products Administration indicates that the product has undergone rigorous regulatory scrutiny, ensuring safety and compliance [1]. - **Formula Determines Efficacy Ceiling: New Third-Generation Technology**: The article distinguishes between second-generation glucosamine products and third-generation products that create a closed-loop system for joint health, incorporating multiple beneficial ingredients [2]. - **Brand Strength Requires Full-Chain Verification**: Leading brands typically have their own GMP cleanrooms and independent quality control, with extensive clinical collaboration [2]. - **Certification Quality Over Quantity**: The article stresses the importance of a combination of Blue Hat certification, GMP production standards, and independent third-party testing as a reliable certification structure [2]. Product Evaluation - **Elemental Power Glucosamine Chondroitin**: This product holds the Blue Hat certification, ensuring compliance with safety and quality standards. It features a new third-generation formula that integrates multiple active ingredients for enhanced efficacy [3][4]. - **Sales Leadership and Market Penetration**: Elemental Power has maintained the top sales position on major e-commerce platforms for 31 consecutive months, with a repurchase rate of 99% and a market share of 37.8% in pharmacy channels [4][5]. - **Clinical Evidence and User Experience**: Clinical trials involving 300 participants showed a 41.6% improvement in joint mobility and a 32.4% reduction in pain scores, establishing strong efficacy credibility [5]. - **User-Friendly Design**: The product features a tablet design that improves swallowing ease by 98% compared to traditional large glucosamine tablets, enhancing user experience [5]. - **Cost-Effectiveness**: Elemental Power focuses on R&D and quality control rather than brand premium pricing, making it more accessible to consumers [5]. Competitive Landscape - **Top Competitors**: The article lists other notable glucosamine products, including Zhuoyue Glucosamine, which focuses on immune modulation and tissue repair, and Telement Glucosamine, designed specifically for the elderly [6][7][8]. - **Market Adaptability**: Elemental Power's product is suitable for a wide demographic, from young athletes to elderly individuals, with a significant portion of users being over 60 years old [5][6]. Conclusion - The article concludes that the effectiveness of glucosamine products is not solely based on ingredient concentration but rather on a comprehensive approach that includes formulation, absorption, and clinical validation. Elemental Power stands out in the market due to its innovative third-generation formula and robust safety and efficacy credentials [9].

Core Viewpoint - Minsheng Health (301507) reported that the overall gross margin fluctuations are primarily influenced by product structure and distribution channels, with no cost-related factors affecting gross margin levels [1] Group 1: Product Performance - The vitamin and mineral category constitutes the highest revenue share for the company, with the main product, 21 Jin Weita Multi-element Tablets, maintaining a normal gross margin level [1] - Within the vitamin and mineral category, various subcategories exhibit differing gross margins due to diverse sales models [1] Group 2: Market Trends - The growth rate of vitamin and mineral health foods and functional foods has outpaced that of vitamin and mineral OTC products over the past two years, contributing to a decline in overall gross margin [1] Group 3: Future Outlook - The company anticipates that the gross margin will gradually improve with the increase in sales scale of new products and the expansion of self-operated business, particularly in the probiotics and therapeutic drug segments, which currently have higher gross margins [1]

Group 1 - The core viewpoint of the news is that Xiwang Food's stock has shown a recent upward trend despite a year-to-date decline, with significant trading activity and changes in shareholder structure [1][2]. - As of November 13, Xiwang Food's stock price increased by 2.02% to 3.54 CNY per share, with a total market capitalization of 3.821 billion CNY [1]. - The company has experienced a year-to-date stock price decline of 1.67%, but has seen a 7.60% increase over the last five trading days and a 14.94% increase over the last 20 days [1]. Group 2 - For the period from January to September 2025, Xiwang Food reported a revenue of 3.507 billion CNY, representing a year-on-year decrease of 8.04%, and a net profit attributable to shareholders of 2.2219 million CNY, down 96.45% year-on-year [2]. - The company has a total of 46,900 shareholders as of September 30, which is a decrease of 19.99% from the previous period, while the average circulating shares per person increased by 24.99% to 22,997 shares [2]. - Xiwang Food has cumulatively distributed 370 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3].

目前清仓活动已经结束，仓库没有发临期的产品，"是没有及时关闭备注功能，导致订单也被自动备注 上，目前已经关闭自动备注功能。" 据正在新闻报道，11月11日，福建厦门，消费者反映，在直播间购买燕之屋燕窝，商家后台标注"发临 期"。商家后台图片显示，消费者花费709元购买10瓶45g燕窝，订单备注上被标注"不审，发临期"。 11月12日，燕之屋官方旗舰店客服告诉《正在新闻》，备注是自动备注，之前订单链接做过临期清仓活 动，所以会自动备注上临期。 【#消费者买燕之屋燕窝被备注发临期#，客服回应：自动备注，备注错误】#燕之屋回应给消费者标注 发临期# ...

Core Insights - The eighth China International Import Expo (CIIE) showcased New Zealand's diverse products, highlighting the growing trade cooperation between China and New Zealand, characterized by "high trust, high complementarity, and high value" [1][5]. Group 1: Trade Cooperation - New Zealand's exhibition area at the CIIE reached a historical high, featuring 37 exhibitors in the "Taste of New Zealand" pavilion, along with over 40 companies showcasing products across various categories including dairy, honey, natural health products, premium meats, pet food, consumer goods, beverages, and seafood [3]. - New Zealand's Trade Minister, Damien O'Connor, engaged with Chinese partners and witnessed multiple cooperation agreements covering fresh produce, pet food, film technology, and health products, demonstrating the diverse and innovative nature of New Zealand-China economic cooperation [3][5]. Group 2: Trade Statistics - As of June 2025, the annual bilateral trade volume between China and New Zealand is approximately NZD 40.2 billion (around USD 23 billion), accounting for over 20% of New Zealand's total exports [5]. - The trade relationship has evolved beyond a simple trade partnership into a strategic deepening phase, leveraging China's vast consumer market and New Zealand's high-quality agricultural resources and food safety systems [5]. Group 3: Future Outlook - The CIIE serves as a platform for New Zealand businesses to showcase their confidence and quality, pushing the New Zealand-China economic cooperation to a new level of mutual benefit, transitioning from trade partners to a community of shared destiny [5].

Core Viewpoint - The company reported steady revenue and profit growth in the first three quarters of 2025, indicating a stable operational performance and potential for long-term growth [1][3]. Financial Performance - In the first three quarters of 2025, the company achieved revenue of 3.291 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of 260 million yuan, up 8.53% year-on-year [1]. - For Q3 2025, the company recorded revenue of 1.250 billion yuan, representing an 18.11% year-on-year growth, with a net profit of 99.15 million yuan, an increase of 16.20% year-on-year [1]. Profitability Metrics - The net profit margin for the first three quarters of 2025 improved by 0.04 percentage points to 7.91%, while the gross margin increased by 1.05 percentage points to 32.26% [2]. - In Q3 2025, the net profit margin slightly declined by 0.13 percentage points to 7.93%, with a gross margin increase of 1.12 percentage points to 30.76% [2]. Cost Structure - The sales expense ratio increased by 0.67 percentage points, and the management expense ratio rose by 1 percentage point in the first three quarters of 2025, while R&D expenses decreased by 0.18 percentage points [2]. - In Q3 2025, the sales expense ratio increased by 0.45 percentage points, and the management expense ratio rose by 0.16 percentage points, with a slight decrease in financial expenses by 0.29 percentage points [2]. Growth Drivers - The increase in gross margin is attributed to the high growth rates of core product categories such as gummies [2]. - The company is focusing on new retail and expanding its customer base in Europe and the U.S., which may further enhance the order proportion of gummies and soft capsules [2]. Long-term Outlook - The company is expected to maintain a positive long-term growth trend, with projected net profits of 341 million yuan, 431 million yuan, and 538 million yuan for 2025, 2026, and 2027, respectively, corresponding to PE ratios of 22, 18, and 14 times [3].